ArticleJournal of translational medicine2026
Innovative multi-epitope vaccine engineering for dual protection against Salmonella and Shigella leveraging FliC flagellin protein adjuvant properties: an immunoinformatics-based approach.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundShigellosis and salmonellosis are prominent food-borne illnesses associated with high mortality rates and morbidity, for which, as of now, no licensed vaccine is available. Multiple epitope vaccines offer promising prospects as alternatives to conventional vaccines by combining extremely immunogenic as well as conserved epitopes to overcome weaknesses related to weak antigens as well as serotype specificity.
methodsFor the first time, this study focused on developing a new protective multiepitope vaccine for dual protection against Salmonella and Shigella by integrating six conserved virulence factors: SpvB, SipD, RcK, SigA, IpaD, and FimA.
resultsWhen immunoinformatics tools were applied, highly conserved B- and T-cell epitopes with broad HLA allele coverage and high antigenicity were predicted, while allergenicity and toxicity assessments were used to assess safety. The selected epitopes were conjugated with suitable spacers to maintain structural integrity and increase immune processing. The conserved domain of the Salmonella flagellin protein (FliC) was used as both the scaffold and the TLR5 agonist adjuvant. Secondary and tertiary FliC-based multiepitope construct (FMEC) structures were predicted, refined, and validated; these structures exhibited desirable physicochemical properties, such as stability, hydrophilicity, and thermal resilience, with a molecular weight of 33 kDa, which is ideal for vaccine construction. In addition, ProSA and Ramachandran plot validation confirmed the reliability of the FMEC model. Immune simulation demonstrated powerful cellular and humoral immunity, whereas molecular docking and normal mode analysis confirmed the stable interaction of FMEC with the TLR4/5 or MHCI/MHCII receptors.
conclusionAlthough FMEC shows promise as a safe, nontoxic, nonallergen, and widely immunogenic multiepitope vaccine candidate to combat Salmonella and Shigella, further experimental validation needs to be carried out to ascertain its in vivo protective efficacy.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.